RIBSP allantoic split inactivated seasonal influenza vaccine

The RIBSP allantoic split inactivated seasonal influenza vaccine is a trivalent, egg-derived, split-virion vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. It contains inactivated influenza virus strains of subtypes A (H1N1pdm09 and H3N2) and type B, standardized to 15 µg of hemagglutinin per strain per 0.5 ml dose. The vaccine is produced using allantoic fluid from embryonated chicken eggs and is notably formulated without adjuvants or preservatives. It is designed to induce protective antibody responses against seasonal influenza by targeting the viral hemagglutinin surface protein. Clinical evaluation has reached Phase II, where it demonstrated safety and immunogenicity comparable to the commercial vaccine Vaxigrip in healthy adults aged 18-60 and over 60 years.

Other names

Allantoic Split Inactivated Seasonal flu VaccineRIBSP influenza vaccine